Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax ® intranasal ...
Aptar Beauty’s sampling solutions and mini packaging provide reliable dispensing, portability, and a consistent brand experience. Our portfolio includes paper-based fragrance sampling, spray vials, ...
Aptar today announced the expansion of its operations in Mumbai, India to add local production of several pharma inhalation technologies, including Aptar’s pressurized metered dose inhaler (pMDI) ...
Aptar Beauty and BVLGARI won the Formes de Luxe Award 2026 in the Refill category. The Le Gemme Tygar Travel Spray is a custom luxury fragrance mini packaging based on the Nomad Refill technology.
Aptar Pharma, a global leader in drug delivery, dosing and protection technologies and services, today announced a new research collaboration with Macquarie University under an Australian Research ...
Aptar Beauty and BVLGARI launch Le Gemme Tygar Travel Spray using Nomad Refill, a refillable 10 ml travel spray that connects directly to a full-size perfume bottle through a patented integrated ...
In this interview, Edouard Pagnoud, Product Line Manager for Vial Stoppers at Aptar Pharma, discusses the evolving expectations for elastomeric closures under USP <382>. He explains the importance of ...
Aptar Beauty expands its Advance Collection with Novus Advance, a full-polyolefin cosmetic pump for hair and body care that is recyclable in the PET and PE streams when paired with compatible HDPE, PP ...
Transfer of Aptar Pharma’s Advanced Preservative Free pump technology to Berazategui, Argentina, strengthens local manufacturing capabilities and supports the company’s local-for-local approach in the ...
Primary packaging has evolved beyond function into a strategic asset and lever for growth for beauty brands seeking to stand out in an increasingly saturated and fast-paced market. More than a visual ...
The development program will support inhaled formulation development and device assessment for Aceso's ACT-101 candidate, reinforcing Aptar Pharma's upstream services capabilities in inhaled biologic ...
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% to over $1 billion for the first time, and core ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results